探究衰弱在阿尔茨海默病神经病理学与痴呆关系中的调节作用:来自拉什记忆和衰老项目的横断面数据分析。
Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project.
机构信息
Geriatric Medicine Research, Centre for Health Care of the Elderly, Nova Scotia Health Authority, Halifax, NS, Canada; Department of Medicine, Dalhousie University, Halifax, NS, Canada.
Rush Alzheimer's Disease Center, Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
出版信息
Lancet Neurol. 2019 Feb;18(2):177-184. doi: 10.1016/S1474-4422(18)30371-5.
BACKGROUND
Some people with substantial Alzheimer's disease pathology at autopsy had shown few characteristic clinical symptoms or signs of the disease, whereas others with little Alzheimer's disease pathology have been diagnosed with Alzheimer's dementia. We aimed to examine whether frailty, which is associated with both age and dementia, moderates the relationship between Alzheimer's disease pathology and Alzheimer's dementia.
METHODS
We did a cross-sectional analysis of data from participants of the Rush Memory and Aging Project, a clinical-pathological cohort study of older adults (older than 59 years) without known dementia at baseline, living in Illinois, USA. Participants in the cohort study underwent annual neuropsychological and clinical evaluations. In the present cross-sectional analysis, we included those participants who did not have any form of dementia or who had Alzheimer's dementia at the time of their last clinical assessment and who had died and for whom complete autopsy data were available. Alzheimer's disease pathology was quantified by a summary measure of neurofibrillary tangles and neuritic and diffuse plaques. Clinical diagnosis of Alzheimer's dementia was based on clinician consensus. Frailty was operationalised retrospectively using health variable information obtained at each clincial evaluation using the deficit accumulation approach (41-item frailty index). Logistic regression and moderation modelling were used to assess relationships between Alzheimer's disease pathology, frailty, and Alzheimer's dementia. All analyses were adjusted for age, sex, and education.
FINDINGS
Up to data cutoff (Jan 20, 2017), we included 456 participants (mean age at death 89·7 years [SD 6·1]; 316 [69%] women). 242 (53%) had a diagnosis of possible or probable Alzheimer's dementia at their last clinical assessment. Frailty (odds ratio 1·76, 95% CI 1·54-2·02; p<0·0001) and Alzheimer's disease pathology (4·81, 3·31-7·01; p<0·0001) were independently associated with Alzheimer's dementia, after adjusting for age, sex, and education. When frailty was added to the model for the relationship between Alzheimer's disease pathology and Alzheimer's dementia, model fit improved (p<0·0001). There was a significant interaction between frailty and Alzheimer's disease pathology (odds ratio 0·73, 95% CI 0·57-0·94; p=0·015). People with an increased frailty score had a weakened direct link between Alzheimer's disease pathology and Alzheimer's dementia; that is, people with a low amount of frailty were better able to tolerate Alzheimer's disease pathology, whereas those with higher amounts of frailty were more likely both to have more Alzheimer's disease pathology and for it to be expressed as dementia.
INTERPRETATION
The degree of frailty among people of the same age modifies the association between Alzheimer's disease pathology and Alzheimer's dementia. That frailty is related to both odds of Alzheimer's dementia and disease expression has implications for clinical management, since individuals with even a low level of Alzheimer's disease pathology might be at risk for dementia if they have high amounts of frailty. Further research should assess how frailty and cognition change over time to better elucidate this complex relationship.
FUNDING
None.
背景
一些在尸检中存在大量阿尔茨海默病病理的患者表现出很少的疾病特征性临床症状或体征,而另一些阿尔茨海默病病理较少的患者则被诊断为阿尔茨海默病痴呆。我们旨在研究衰弱(与年龄和痴呆症有关)是否会调节阿尔茨海默病病理学与阿尔茨海默病痴呆症之间的关系。
方法
我们对来自伊利诺伊州美国的 Rush 记忆和衰老项目的参与者进行了横断面数据分析,该项目是一项针对年龄在 59 岁以上且基线时无已知痴呆症的老年人的临床病理队列研究。队列研究的参与者每年接受神经心理学和临床评估。在本次横断面分析中,我们纳入了那些没有任何形式的痴呆症或在最后一次临床评估时患有阿尔茨海默病痴呆症且已死亡且完整尸检数据可用的参与者。阿尔茨海默病病理学通过神经原纤维缠结和神经原纤维和弥散斑块的综合测量来量化。基于临床医生共识的临床诊断为阿尔茨海默病痴呆症。采用缺陷累积方法(41 项衰弱指数)回顾性地使用每次临床评估获得的健康变量信息来确定衰弱情况。使用逻辑回归和调节模型来评估阿尔茨海默病病理学、衰弱和阿尔茨海默病痴呆症之间的关系。所有分析均根据年龄、性别和教育进行调整。
发现
截至 2017 年 1 月 20 日的数据截止日期,我们纳入了 456 名参与者(死亡时的平均年龄为 89.7 岁[标准差 6.1];316 名[69%]为女性)。242 名(53%)在最后一次临床评估时被诊断为可能或很可能患有阿尔茨海默病痴呆症。衰弱(比值比 1.76,95%CI 1.54-2.02;p<0.0001)和阿尔茨海默病病理学(4.81,3.31-7.01;p<0.0001)在调整年龄、性别和教育后与阿尔茨海默病痴呆症独立相关。当将衰弱纳入阿尔茨海默病病理学与阿尔茨海默病痴呆症之间关系的模型中时,模型拟合得到改善(p<0.0001)。衰弱与阿尔茨海默病病理学之间存在显著的交互作用(比值比 0.73,95%CI 0.57-0.94;p=0.015)。衰弱评分较高的人在阿尔茨海默病病理学与阿尔茨海默病痴呆症之间的直接关联较弱;也就是说,衰弱程度较低的人能够更好地耐受阿尔茨海默病病理学,而衰弱程度较高的人更容易同时患有更多的阿尔茨海默病病理学,并且更容易表现为痴呆症。
解释
相同年龄的人的衰弱程度会改变阿尔茨海默病病理学与阿尔茨海默病痴呆症之间的关联。衰弱与阿尔茨海默病痴呆症的发生几率和疾病表现都有关,这对临床管理有影响,因为即使是轻度阿尔茨海默病病理学的个体,如果衰弱程度较高,也可能有痴呆症的风险。进一步的研究应评估衰弱和认知功能随时间的变化,以更好地阐明这种复杂的关系。
资金
无。
相似文献
Acta Neuropathol Commun. 2019-7-3
引用本文的文献
Aging Clin Exp Res. 2025-8-31
J Cachexia Sarcopenia Muscle. 2025-8
Acta Neuropathol Commun. 2025-7-14
Alzheimers Res Ther. 2025-7-12
Clin Interv Aging. 2025-3-4
本文引用的文献
Alzheimers Dement (Amst). 2018-5-30
Ann Neurol. 2018-1-14
Sci Rep. 2017-3-14
Neurology. 2017-2-14
J Alzheimers Dis. 2016-6-15
Alzheimers Res Ther. 2015-8-3
Curr Opin Clin Nutr Metab Care. 2015-1
Alzheimers Res Ther. 2014-9-18